Liver allograft radiotherapy to treat rejection in children: efficacy in orthotopic liver transplantation and long-term safety

Liver Int. 2005 Dec;25(6):1108-13. doi: 10.1111/j.1478-3231.2005.01152.x.

Abstract

Background: We studied, retrospectively, the efficacy to control rejection and long-term safety of liver allograft radiotherapy (RT) performed in 14 children. Long-term safety data were collected with the prospect of possible use of RT in liver cell transplantation (LCT).

Methods: Immune suppression included cyclosporine, azathioprine and prednisone. In case of intractable rejection, low-dose allograft RT was administered daily for 3 days, and short-term efficacy was evaluated by liver enzyme assays and histology. The long-term outcome was compared with that of 122 patients undergone transplantation and who had similar treatment, but no RT.

Results: Survival at 15 years was 71.4% vs 69.7% in the comparison group. In the RT group, rejection control was complete in six of 14 children and partial in two, all being alive and well 14-18 years later. Ten of 14 children had follow-up biopsy. Six children had normal histology and four had mild unspecific fibrosis. The long-term follow-up biopsy in the comparison group showed fibrosis in 42 of 85 children. The incidence of complications was similar in both groups.

Conclusions: This series shows that, such a RT regimen appeared to be efficient and safe as a rescue treatment for acute rejection. Provided that further investigations in animal models show a certain benefit of low-dose irradiation around LCT, such a regimen could be proposed in human liver cell transplant programmes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Child, Preschool
  • Graft Rejection / drug therapy
  • Graft Rejection / mortality
  • Graft Rejection / radiotherapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Liver Transplantation*
  • Radiotherapy / adverse effects
  • Radiotherapy Dosage
  • Salvage Therapy
  • Survival Rate

Substances

  • Immunosuppressive Agents